Walter Ageno to Rivaroxaban
This is a "connection" page, showing publications Walter Ageno has written about Rivaroxaban.
Connection Strength
2.006
-
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. Br J Haematol. 2018 11; 183(3):457-465.
Score: 0.548
-
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thromb Res. 2017 Jul; 155:23-27.
Score: 0.499
-
Direct oral anticoagulants for superficial-vein thrombosis. Lancet Haematol. 2017 03; 4(3):e95-e96.
Score: 0.494
-
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. Eur J Intern Med. 2019 03; 61:29-33.
Score: 0.139
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.137
-
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert Rev Cardiovasc Ther. 2009 Jun; 7(6):569-76.
Score: 0.072
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
Score: 0.035
-
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med. 2018 Oct; 13(7):1051-1058.
Score: 0.034
-
Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med. 2017 Apr; 12(3):387-406.
Score: 0.031
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26; 358(26):2776-86.
Score: 0.017